VIRXViracta Therapeutics Inc

$0.00
$0.00
(0.00%)
Today
Updated:
Reported EarningsNov 13
Mkt Cap$388,699.00
Vol484,026.00

About

Viracta Therapeutics, Inc. a clinical-stage, biomarker-directed precision oncology company focused on new medicines for the treatment of virus-associated malignancies. It develops antiviral agent valganciclovir as an oral combination therapy which is in a Phase 2 clinical trial for EBV-positive lymphomas. The company was founded on February 10, 1998 and is headquartered in Cardiff, CA.
Sector:
Health Technology
Industry:
Pharmaceuticals Major
Employees:
N/A

Frequently Asked Questions

What is Market Cap of Viracta Therapeutics Inc?
What is the 52-week high for Viracta Therapeutics Inc?
What is the 52-week low for Viracta Therapeutics Inc?
What is Viracta Therapeutics Inc stock price today?
What was Viracta Therapeutics Inc stock price yesterday?
What is the PE ratio of Viracta Therapeutics Inc?
What is the Price-to-Book ratio of Viracta Therapeutics Inc?
What is the 50-day moving average of Viracta Therapeutics Inc?

Latest VIRX News

View

Advertisement|Remove ads.

Advertisement|Remove ads.